Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-guided response-adapted therapy in untreated high-tumor-burden follicular lymphoma
ISRCTN86739591Phase 3Active, not recruiting
- Sponsor
- University of Liverpool
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rituximab, lenalidomide, cyclophosphamide, vincristine, prednisolone and 2 more in follicular lymphoma (FL) (4 arms), sponsored by University of Liverpool. Primary endpoint: Progression-free survival. Started May 2018; status: active, not recruiting.
02
Drugs
rituximablenalidomidecyclophosphamidevincristineprednisolone
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ISRCTN86739591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86739591.